Arq - Q3 2026 Earnings Call - ARQ INC

Financial Performance:

• Q3 2026 revenue reached a record $38.2 million, a 9% year-over-year increase, bringing full-year 2026 guidance to $120–$125 million.
• Gross margin expanded significantly to 39.7% in Q3 2026 compared to 28.8% in the prior year period.
• Adjusted EBITDA was $8.8 million for Q3 2026 (vs. $5.2 million YoY), marking the 10th consecutive quarter of positive adjusted EBITDA; full-year adjusted EBITDA guidance raised to $19–$20 million (previously $17–$20 million).
• Net income turned positive at $2.5 million for Q3 2026, contrasting with a $0.9 million net loss in the prior year.
• SG&A expenses increased to $7.2 million (vs. $4.6 million YoY) primarily due to higher incentive compensation and legal fees, while R&D costs decreased to $0.8 million (vs. $2.6 million) due to non-recurring GAC ramp-up costs in the prior year.
• Cash position ended Q3 at $19.1 million total ($7.8 million unrestricted), with total debt reduced to $28.2 million.
• Operating cash flow generation is highlighted as improving due to disciplined management and higher profitability.

Guidance and Future Outlook:

• 2026 full-year adjusted EBITDA guidance tightened and raised to the top of the previous range ($19–$20 million) due to strong year-to-date performance exceeding 2025 full-year results ($17.4 million YTD vs. $13 million in 2025).
• Full-year revenue guidance reiterated at $120–$125 million; CapEx guidance remains $8–$10 million.
• Management expects to deliver material profitability growth in 2027, targeting an adjusted EBITDA run rate of approximately $30 million by year-end, driven by organic growth, cost efficiencies, and new product lines.
• PAC for PFAS is expected to be a meaningful revenue contributor in 2027, with revenues anticipated to be back-end loaded as testing cycles complete.
• Formal 2027 guidance, including specific volume and pricing targets, will be provided early in 2027.

Business Segments and Product Lines:

• The foundational Powdered Activated Carbon (PAC) business is the primary growth engine, delivering record volumes, revenue, and margins organically.
• PAC for PFAS is the immediate strategic priority for remediation; it utilizes existing equipment with little to no capital expenditure, offering superior margins compared to Granular Activated Carbon (GAC) in the near term.
• Testing for PAC for PFAS is ongoing with over a dozen customers; test volumes have been sold at prices materially above traditional PAC averages, with successful removal of lower-level PFAS and taste/odor issues demonstrated.
• GAC project remains an optionality for the 2029–2031 compliance window rather than a near-term revenue driver; strategic optimization is complete, and a decision on funding and timing is pending.
• Corbin asset monetization is underway, with asphalt as the primary path; site carries ~$8 million debt and ~$1.2M annual operating costs, with a target to monetize within 12 months.
• New operations leadership (Thad Ratliff) has been installed to drive efficiency, replacing interim leadership.

Market and Competitive Landscape:

• The PFAS remediation market is described as robust and growing, driven by the upcoming April 2027 monitoring and reporting deadline and potential EPA thresholds.
• Market prices for remediation solutions are rising due to high customer demand and limited supply.
• The addressable market for PAC for PFAS is conservatively estimated at 160 million pounds per year by 2029.
• ARC maintains strong relationships with municipal water authorities and private utilities, leveraging these connections to accelerate customer trials and contract discussions.
• Competition involves standard market products, but ARC's PAC for PFAS has demonstrated outperformance in early tests.

Risks and Challenges:

• Regulatory compliance timelines (EPA thresholds) create pressure, though customer proactivity is a positive market driver.
• The Corbin asset monetization timeline is uncertain and could be delayed beyond 12 months; it remains a variable in short-term financial expectations.
• Future decisions on GAC production are contingent on securing acceptable funding and ensuring a favorable return profile.
• The company acknowledges that actual results may differ from forward-looking statements due to market volatility, regulatory changes, and execution risks.

Management Commentary and Tone:

• Management tone is confident and focused on rebuilding investor credibility by consistently meeting or beating guidance.
• Emphasis is placed on capital efficiency, noting that significant growth is achievable without substantial new capital expenditure.
• The balance sheet is described as robust and strengthening, with plans to refinance the mid-cap credit facility to reduce costs and reporting burdens within six months.
• There is a clear strategic pivot toward maximizing profitability through cost savings, pricing power, and the high-margin PAC for PFAS product line.
• Management expressed belief that the market currently undervalues the company due to a misunderstanding of the PFAS opportunity and balance sheet strength.

Analyst Questions and Answers:

• Testing and Sales Timeline: PAC for PFAS testing takes 1–3 months with concurrent contract discussions; revenue contribution is expected to materialize in 2027 and be back-end loaded.
• Margin Expansion: Gross margin expansion to 39.7% was driven by volume growth and an ~8% reduction in costs; future expansion expected via efficiency initiatives and higher-priced PFAS products.
• Pricing vs. Capacity: If capacity constraints arise, the company plans to prioritize higher-margin segments (PAC for PFAS) and potentially eliminate lower-margin volumes.
• GAC vs. PAC for PFAS: The decision to proceed with GAC is not dependent on PAC for PFAS adoption but on the availability of acceptable funding and a strong return profile; PAC for PFAS is prioritized now due to superior cash margins and zero CapEx.
• Leadership Transition: Thad Ratliff's appointment as SVP of Operations replaces interim leadership; the move is timed to focus on existing operations before any potential future GAC construction.

Other Key Points:

• ARC has successfully delivered on its strategic optimization review, identifying over 15 efficiency opportunities across eight departments.
• The company holds pending patent protection for its advanced PAC for PFAS product line.
• The company's existing Net Operating Losses (NOLs) position it to convert operating profit directly into net income.
• The strategic focus remains on the "portfolio approach" to PFAS, utilizing multiple product lines (PAC, GAC, other) as market demands and deadlines evolve.